Role of midazolam on cancer progression/survival - An updated systematic review
Background and Aims: Cancer is a leading cause of mortality worldwide. Despite advancements in cancer management, cancer progression remains a challenge, requiring the development of novel therapies. Midazolam is a commonly used adjunct to anaesthesia care for various surgeries, including cancer. Re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Anaesthesia |
| Subjects: | |
| Online Access: | http://www.ijaweb.org/article.asp?issn=0019-5049;year=2023;volume=67;issue=11;spage=951;epage=961;aulast=Sethi |
| _version_ | 1797352112506535936 |
|---|---|
| author | Ansh Sethi Amal Rezk Rachel Couban Tumul Chowdhury |
| author_facet | Ansh Sethi Amal Rezk Rachel Couban Tumul Chowdhury |
| author_sort | Ansh Sethi |
| collection | DOAJ |
| description | Background and Aims: Cancer is a leading cause of mortality worldwide. Despite advancements in cancer management, cancer progression remains a challenge, requiring the development of novel therapies. Midazolam is a commonly used adjunct to anaesthesia care for various surgeries, including cancer. Recently, there has been a growing interest in exploring the potential role of midazolam as an anticancer agent; however, the exact mechanism of this linkage is yet to be investigated thoroughly. Methods: Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, this systematic review presented aggregated evidence (till November 2022) of the effects of midazolam on cancer progression and survival. All primary research article types where midazolam was administered in vivo or in vitro on subjects with cancers were included. No restrictions were applied on routes of administration or the type of cancer under investigation. Narrative synthesis depicted qualitative findings, whereas frequencies and percentages presented numerical data. Results: Of 1720 citations, 19 studies were included in this review. All articles were preclinical studies conducted either in vitro (58%, 11/19) or both in vivo and in vitro (42%, 8/19). The most studied cancer was lung carcinoma (21%, 4/19). There are two main findings in this review. First, midazolam delays cancer progression (89%, 17/19). Second, midazolam reduces cancer cell survival (63%, 12/19). The two major mechanisms of these properties can be explained via inducing apoptosis (63%, 12/19) and inhibiting cancer cell proliferation (53%, 10/19). In addition, midazolam demonstrated antimetastatic properties via inhibition of cancer invasion (21%, 4/19), migration (26%, 5/19), or epithelial-mesenchymal transition (5%, 1/19). These anticancer properties of midazolam were demonstrated through different pathways when midazolam was used alone or in combination with traditional cancer chemotherapeutic agents. Conclusion: This systematic review highlights that midazolam has the potential to impede cancer progression and decrease cancer cell survival. Extrapolation of these results into human cancer necessitates further investigation. |
| first_indexed | 2024-03-08T13:11:33Z |
| format | Article |
| id | doaj.art-a9938340a2024069b5dc41e6ca2ec88b |
| institution | Directory Open Access Journal |
| issn | 0019-5049 0976-2817 |
| language | English |
| last_indexed | 2024-03-08T13:11:33Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Anaesthesia |
| spelling | doaj.art-a9938340a2024069b5dc41e6ca2ec88b2024-01-18T12:28:25ZengWolters Kluwer Medknow PublicationsIndian Journal of Anaesthesia0019-50490976-28172023-01-01671195196110.4103/ija.ija_731_23Role of midazolam on cancer progression/survival - An updated systematic reviewAnsh SethiAmal RezkRachel CoubanTumul ChowdhuryBackground and Aims: Cancer is a leading cause of mortality worldwide. Despite advancements in cancer management, cancer progression remains a challenge, requiring the development of novel therapies. Midazolam is a commonly used adjunct to anaesthesia care for various surgeries, including cancer. Recently, there has been a growing interest in exploring the potential role of midazolam as an anticancer agent; however, the exact mechanism of this linkage is yet to be investigated thoroughly. Methods: Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, this systematic review presented aggregated evidence (till November 2022) of the effects of midazolam on cancer progression and survival. All primary research article types where midazolam was administered in vivo or in vitro on subjects with cancers were included. No restrictions were applied on routes of administration or the type of cancer under investigation. Narrative synthesis depicted qualitative findings, whereas frequencies and percentages presented numerical data. Results: Of 1720 citations, 19 studies were included in this review. All articles were preclinical studies conducted either in vitro (58%, 11/19) or both in vivo and in vitro (42%, 8/19). The most studied cancer was lung carcinoma (21%, 4/19). There are two main findings in this review. First, midazolam delays cancer progression (89%, 17/19). Second, midazolam reduces cancer cell survival (63%, 12/19). The two major mechanisms of these properties can be explained via inducing apoptosis (63%, 12/19) and inhibiting cancer cell proliferation (53%, 10/19). In addition, midazolam demonstrated antimetastatic properties via inhibition of cancer invasion (21%, 4/19), migration (26%, 5/19), or epithelial-mesenchymal transition (5%, 1/19). These anticancer properties of midazolam were demonstrated through different pathways when midazolam was used alone or in combination with traditional cancer chemotherapeutic agents. Conclusion: This systematic review highlights that midazolam has the potential to impede cancer progression and decrease cancer cell survival. Extrapolation of these results into human cancer necessitates further investigation.http://www.ijaweb.org/article.asp?issn=0019-5049;year=2023;volume=67;issue=11;spage=951;epage=961;aulast=Sethicancercancer progressioncell linemetastasismidazolamneoplasmssurgerysurgical proceduressurvival |
| spellingShingle | Ansh Sethi Amal Rezk Rachel Couban Tumul Chowdhury Role of midazolam on cancer progression/survival - An updated systematic review Indian Journal of Anaesthesia cancer cancer progression cell line metastasis midazolam neoplasms surgery surgical procedures survival |
| title | Role of midazolam on cancer progression/survival - An updated systematic review |
| title_full | Role of midazolam on cancer progression/survival - An updated systematic review |
| title_fullStr | Role of midazolam on cancer progression/survival - An updated systematic review |
| title_full_unstemmed | Role of midazolam on cancer progression/survival - An updated systematic review |
| title_short | Role of midazolam on cancer progression/survival - An updated systematic review |
| title_sort | role of midazolam on cancer progression survival an updated systematic review |
| topic | cancer cancer progression cell line metastasis midazolam neoplasms surgery surgical procedures survival |
| url | http://www.ijaweb.org/article.asp?issn=0019-5049;year=2023;volume=67;issue=11;spage=951;epage=961;aulast=Sethi |
| work_keys_str_mv | AT anshsethi roleofmidazolamoncancerprogressionsurvivalanupdatedsystematicreview AT amalrezk roleofmidazolamoncancerprogressionsurvivalanupdatedsystematicreview AT rachelcouban roleofmidazolamoncancerprogressionsurvivalanupdatedsystematicreview AT tumulchowdhury roleofmidazolamoncancerprogressionsurvivalanupdatedsystematicreview |